Author(s):
Abinash Satapathy, Neha Yadav, Trilochan Satapathy, Kalpana Sen, Shailesh Sahu, Ayushi Gupta, Bharti Pradhan, Shiv Kumar Bhardwaj
Email(s):
vickysatapathy@gmail.com
DOI:
10.52711/2321-5836.2024.00023 
Address:
Abinash Satapathy1*, Neha Yadav1, Trilochan Satapathy2, Kalpana Sen2, Shailesh Sahu2, Ayushi Gupta2, Bharti Pradhan2, Shiv Kumar Bhardwaj2
1College of Veterinary Science and Animal Husbandry, Anjora - 491001, Durg, C.G., India.
2Columbia Institute of Pharmacy, Raipur, 493111, Chhattisgarh.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2024
ABSTRACT:
The viral pandemic in India has presented a complex and challenging scenario since 2019, impacting the nation's public health, economy, and social fabric. This abstract provides a concise overview of the key aspects concerning the new virus H9N2. H9N2 is primarily an avian influenza virus, and while it has occasionally infected humans, those cases have generally been limited and the virus has not shown sustained human-to-human transmission. This paper explores the structural components of H9N2, determinant of host tropism, antigenic characteristics, transmission pattern, and symptoms after viral entry, complications, preventive measures, therapeutic measures, research and surveillance and role of Government for prevention and eradication of viral pandemic and measures need to be taken by the government to mitigate economic fallout etc. Special attention is given to the identification of hotspots and the effectiveness of containment measures. The abstract concludes with an exploration of the challenges faced many countries during the viral pandemic during the recent past and the lessons learned in terms of preparedness, response mechanisms, and the need for global cooperation in addressing future pandemics. Paper also serves as a snapshot of the multifaceted impact of the viral pandemic in India, offering insights into the country's response strategies and the broader implications for public health and society.
Cite this article:
Abinash Satapathy, Neha Yadav, Trilochan Satapathy, Kalpana Sen, Shailesh Sahu, Ayushi Gupta, Bharti Pradhan, Shiv Kumar Bhardwaj. H9N2: A Mysterious Avian Influenza Virus: A Global Threat for Respiratory Pneumonia. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(2):127-3. doi: 10.52711/2321-5836.2024.00023
Cite(Electronic):
Abinash Satapathy, Neha Yadav, Trilochan Satapathy, Kalpana Sen, Shailesh Sahu, Ayushi Gupta, Bharti Pradhan, Shiv Kumar Bhardwaj. H9N2: A Mysterious Avian Influenza Virus: A Global Threat for Respiratory Pneumonia. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(2):127-3. doi: 10.52711/2321-5836.2024.00023 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-2-12
REFERENCES:
1. WANG YanWen, WANG MengJing, ZHANG Hong, GAO Xin Xin, GUO Jing, LI XuYong. Evolution of Human H9N2 Avian Influenza Virus in China from 1998 to 2021[J]. Scientia Agricultura Sinica. 2022; 55(20): 4075-4090.
2. Sorrell EM, Wan H, Araya Y, Song H, Perez DR. Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proc Natl Acad Sci USA. 2009; 106: 7565–7570.
3. National Institute of Allergy and Infectious Diseases NIH http://www3.niaid.nih.gov/news/focuson/flu/illustrations/timeline/2007
4. Kand un IN, Wibisono H, Sedyaningsih ER, Yusharmen HW, Purba W, Santoso H, Septiawati C, Tresnaningsih E, Heriyanto B et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006; 355:2186–2194.
5. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12:1203–1207.
6. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol. 2005; 43: 5760–5767.
7. Vandna Dewangan, Ram Sahu, Trilochan Satapathy, Amit Roy. The Exploring of Current Development status and the unusual Symptoms of coronavirus Pandemic (Covid-19). 12(4): 172-176.
8. John Lenard a, Richard W. Compans. The mem brane structure of lipid-containing viruses. Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes.1974; 344(1): 51-94.
9. Wiley DC and Skehel JJ. The Structure and Function of the Hemagglutinin Membrane Glycoprotein of Influenza Virus. Annual Review of Biochemistry. 1987; 56: 365-394.
10. Böttcher-Friebertshäuser E, Garten W, Matrosovich M, Klenk HD. The Hemagglutinin: A Determinant of Pathogenicity. Influenza Pathogenesis and Control. 2014; 1: 3–34.
11. McAuley JL, Gilbertson BP, Trifkovic S, Brown LE and McKimm-Breschkin JL. Influenza Virus Neuraminidase Structure and Functions. Frontiers in Microbiology. 2019; 10: 39.
12. Schulze IT. The structure of influenza virus: I. The polypeptides of the virion. Virology. 1970; 42(4): 890-904.
13. Stevaert A, Naesens L. The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design. Medical Research Reviews. 2016; 36(6): 1127-173.
14. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proceedings of the National Academy of Sciences. 2000; 97(17): 9654-8.
15. Rahimi Rad S, Alizadeh A, Alizadeh E, Hosseini SM. The avian influenza H9N2 at avian-human interface: A possible risk for the future pandemics. Journal of Research in Medical Sciences. 2016; 21: 51.
16. Heidari A, Mancin M, Nili H, Pourghanbari GH, Lankarani KB, Leardini S, Cattoli G, Monne I, Piccirillo A. Serological evidence of H9N2 avian influenza virus exposure among poultry workers from Fars province of Iran. Virology Journal. 2016; 13(1): 1-9.
17. Turner JC, Feeroz MM, Hasan MK, Akhtar S, Walker D, Seiler P, Barman S, Franks J, Jones-Engel L, McKenzie P, Krauss S. Insight into live bird markets of Bangladesh: an overview of the dynamics of transmission of H5N1 and H9N2 avian influenza viruses. Emerging Microbes & Infections. 2017; 6(1): 1-8.
18. Cáceres CJ, Rajao DS, Perez DR. Airborne transmission of avian origin H9N2 influenza A viruses in mammals. Viruses. 2021; 13(10): 1919.
19. Liu R, Zhao B, Li Y, Zhang X, Chen S, Chen T. Clinical and epidemiological characteristics of a young child infected with avian influenza A (H9N2) virus in China. Journal of International Medical Research. 2018; 46(8): 3462-7.
20. Williams JV. The clinical presentation and outcomes of children infected with newly identified respiratory tract viruses. Infectious Disease Clinics. 2005; 19(3):569-84.
21. Cheng VC, Chan JF, Wen X, Wu WL, Que TL, Chen H, Chan KH, Yuen KY. Infection of immunocompromised patients by avian H9N2 influenza A virus. Journal of Infection. 2011; 62(5): 394-9.
22. Capua I, Cattoli G. Prevention and control of highly pathogenic avian influenza with particular reference to H5N1. Virus research. 2013; 178(1): 114-20.
23. Pusch EA, Suarez DL. The multifaceted zoonotic risk of H9N2 avian influenza. Veterinary Sciences. 2018; 5(4): 82.
24. Cui H, de Jong MC, Beerens N, van Oers MM, Teng Q, Li L, Li X, Liu Q, Li Z. Vaccination with inactivated virus against low pathogenic avian influenza subtype H9N2 does not prevent virus transmission in chickens. Journal of Virus Eradication. 2021; 7(3): 100055.
25. Poetri ON, Nugroho CM, Silaen OS, Kurnia RS, Krisnamurti DG, Indrawati A, Hikmah N, Hariyadi IP, Putra MA, Soebandrio A. Potential of Neuraminidase from Pasteurella multocida for Inhibiting Avian Influenza Virus Subtype H9N2 Replication In Ovo. Tropical Animal Science Journal. 2023; 46(4): 487-93.
26. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Research. 2000; 48(2): 101-15.
27. Mehta K, Goneau LW, Wong J, L’Huillier AG, Gubbay JB. Zoonotic Influenza and Human Health—Part 2: Clinical Features, Diagnosis, Treatment, and Prevention Strategies. Current Infectious Disease Reports. 2018; 20: 1-2.
28. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X. Human infection with a novel avian-origin influenza A (H7N9) virus. New England Journal of Medicine. 2013; 368(20): 1888-97.
29. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. European Respiratory Journal. 2001; 17(6): 1282-93.
30. Blair PJ, Putnam SD, Krueger WS, Chum C, Wierzba TF, Heil GL, Yasuda CY, Williams M, Kasper MR, Friary JA, Capuano AW. Evidence for avian H9N2 influenza virus infections among rural villagers in Cambodia. Journal of Infection and Public Health. 2013; 6(2): 69-79.
31. Kitler ME, Gavinio P, Lavanchy D. Influenza and the work of the World Health Organization. Vaccine. 2002; 20: S5-14.
32. World Health Organization. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza: annex: report of systematic literature reviews. World Health Organization; 2019.